CDK6 and hepatocellular carcinoma: With the anti-cancer properties of miR-26a, which inhibits CDK6 and E2F3 oncogenes in HCC, in mind, Mahati et al. loaded miR-26a in anti-GPC3 scFv-expressing MSC-Exos and evaluated their therapeutic potential against HCC cells [46].